We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Test Could Predict Immunotherapy Success for Broader Range Of Cancers

By LabMedica International staff writers
Posted on 15 Feb 2024
Print article
Image: Correctly identifying which patients will respond to immunotherapy and those who will not is crucial (Photo courtesy of 123RF)
Image: Correctly identifying which patients will respond to immunotherapy and those who will not is crucial (Photo courtesy of 123RF)

Immunotherapy has revolutionized cancer treatment, yet only a minority of patients experience favorable responses. Determining which patients will benefit from immunotherapy is critical, as these treatments can have severe side effects and, in some cases, may even accelerate cancer progression. Now, a new genetic marker has been identified that could predict patient response to immunotherapy in cancer types that previously lacked such predictive tools.

A study led by researchers at the University of Pittsburgh (Pittsburgh, PA, USA) has found that tumors with a higher number of intragenic rearrangements (IGRs) in their genetic code may respond better to immunotherapy. This finding opens the door to more targeted treatment decisions for cancers like breast, ovarian, esophageal, and uterine cancer. Typically, immunotherapy responders are identified by the tumor mutational burden (TMB), which counts the number of simple mutations in cancer cells' DNA. High TMB makes cancer cells more conspicuous to the immune system, making patients with high TMB ideal candidates for immunotherapy. However, this method is more effective for cancers with high mutation rates, such as melanoma and lung cancer.

In their search for a new genetic biomarker to predict immunotherapy success in other cancers, the team analyzed over 1,000 cancer genomes from various types using a large database from the International Cancer Genomic Consortium. They found that assessing the overall IGR burden could predict immune cell infiltration and immunotherapy response in certain cancers. IGRs, resulting from complex structural rearrangements within a gene, contrast with TMB, which is similar to simple typos in DNA. The researchers observed a relationship between IGR and TMB across different tumor types. Cancers with high TMB, like melanoma and lung cancer, had low IGR burdens, while breast, ovarian, endometrial, and esophageal cancers exhibited low TMB but high IGR burdens. Both high IGR and high TMB were associated with increased T cell inflammation, suggesting that either type of genetic abnormality could enhance immune recognition and potential destruction of cancer cells.

In a clinical trial of esophageal cancer patients treated with durvalumab, those with higher IGR burdens responded better to the immunotherapy, while relapsed patients tended to have lower IGR burdens. Another clinical trial with bladder cancer patients treated with atezolizumab showed that TMB, but not IGR burden, predicted response in this TMB-dominant cancer. However, in patients pre-treated with platinum-based chemotherapy, post-chemotherapy IGR burden, but not pre-chemotherapy burden, predicted immunotherapy response. This suggests that platinum exposure, which can induce structural genome rearrangements, affects immunotherapy response. These findings suggest that IGR testing could guide clinicians in selecting optimal treatments for different cancer types and contexts. With the declining cost of whole genome sequencing, measuring IGR burden could soon be both feasible and affordable. The researchers are now focusing on further developing and standardizing their tests and algorithms for clinical application.

“Genetic tests are available that are great at predicting immunotherapy response in melanoma and lung cancer, but they don’t work well in some other cancers,” said Xiaosong (Johnathan) Wang, M.D., Ph.D., associate professor of pathology at Pitt. “To help fill this gap, we developed a new approach, which analyzes a class of hidden, or cryptic, rearrangements in the cancer genome.”

Related Links:
University of Pittsburgh

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.